基于 B-TACE 在肝细胞癌中的临床研究及应用价值
摘要
癌（ICC）和混合型肝细胞癌 - 胆管癌（cHCC-CCA）三种不同病理学类型，其中 HCC 占 75%~85%[1]，最为多见。HCC
的全球发病率上升和死亡率居高不下要求我们采取紧急和创新的措施来改善患者的预后。通过治疗方式的改进、抗肿瘤药
物的开发等，降低 HCC 患者死亡率和改善患者生活质量。球囊闭塞 TACE（B-TACE）作为一种新兴的治疗概念，已在
国际上引起了广泛关注。B-TACE 代表了 TACE 技术的新趋势，在疗效和安全性方面展现出独特的优势。在本综述中，我
们综合了 TACE 治疗的最新研究成果，涵盖了技术创新、联合治疗策略的临床证据，以及探索了 B-TACE 在治疗中晚期
HCC 的潜力。
关键词
全文:
PDF参考
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,
2018,68(6):394-424.DOI: 10.3322/caac.21492.
[2] Sung H, Ferlay J, Siegel R L, et al. Global Cancer
Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality
Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin,
2021,71(3):209-249.DOI: 10.3322/caac.21660.
[3] 李 永 奇 , 刘 婷 婷 , 贾 中 芝 . 《 原 发 性 肝 癌 诊 疗
指 南 (2024 年 版 )》 更 新 要 点 解 读 [J]. 手 术 电 子 杂 志 ,
2024,11(3):20-26.DOI: 10.3969/j.issn.2095-8331.2024.03.007.
[4] Chen W, Zheng R, Baade P D, et al. Cancer statistics
in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132.DOI:
10.3322/caac.21338.
[5] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity,
and risk factors in China and its provinces, 1990-2017: a
systematic analysis for the Global Burden of Disease Study
2017[J]. Lancet, 2019,394(10204):1145-1158.DOI: 10.1016/
S0140-6736(19)30427-1.
[6] 中华人民共和国国家卫生健康委员会 . 原发性
肝 癌 诊 疗 指 南 (2022 年 版 )[J]. 肿 瘤 综 合 治 疗 电 子 杂 志 ,
2022,8(2):16-53.DOI: 10.12151/JMCM.2022.02-04.
[7] Reig M, Forner A, Rimola J, et al. BCLC strategy
for prognosis prediction and treatment recommendation: The
2022 update[J]. J Hepatol, 2022,76(3):681-693.DOI: 10.1016/
j.jhep.2021.11.018.
[8] Shao G, Zou Y, Lucatelli P, et al. Chinese expert
consensus on technical recommendations for the standard
operation of drug-eluting beads for transvascular embolization[J].
Ann Transl Med, 2021,9(8):714.DOI: 10.21037/atm-21-1678.
[9] Lucatelli P, Burrel M, Guiu B, et al. CIRSE Standards
of Practice on Hepatic Transarterial Chemoembolisation[J].
Cardiovasc Intervent Radiol, 2021,44(12):1851-1867.DOI:
10.1007/s00270-021-02968-1.
[10] Boulin M, Hillon P, Cercueil J P, et al. Idarubicin-
loaded beads for chemoembolisation of hepatocellular carcinoma:
results of the IDASPHERE phase I trial[J]. Aliment Pharmacol
Ther, 2014,39(11):1301-1313.DOI: 10.1111/apt.12746.
[11] Guiu B, Chevallier P, Assenat E, et al. Idarubicin-
loaded Beads for Chemoembolization of Hepatocellular Carcinoma:
The IDASPHERE II Single-Arm Phase II Trial[J]. Radiology,
2019,291(3):801-808.DOI: 10.1148/radiol.2019182399.
[12] Tzeng W S, Wu R H, Chang S C, et al. Ionic versus
nonionic contrast media solvents used with an epirubicin-based
agent for transarterial chemoembolization of hepatocellular
carcinoma[J]. J Vasc Interv Radiol, 2008,19(3):342-350.DOI:
10.1016/j.jvir.2007.10.021.
[13] Wu G C, Chan E D, Chou Y C, et al. Risk factors for
the development of pulmonary oil embolism after transcatheter
arterial chemoembolization of hepatic tumors[J]. Anticancer Drugs,
2014,25(8):976-981.DOI: 10.1097/CAD.0000000000000113.
[14] 国家卫生健康委办公厅 . 原发性肝癌诊疗指南
（2022 年 版）[J]. 中 华 外 科 杂 志 , 2022,60(4):273-309.DOI:
10.3760/cma.j.cn112139-20220217-00068.
[15] Daniels J R. Overall survival after transarterial
lipiodol infusion chemotherapy with or without embolization
for unresectable hepatocellular carcinoma: propensity score
analysis[J]. AJR Am J Roentgenol, 2011,196(2):W220.DOI:
10.2214/AJR.10.4558.
[16] Raoul J L, Forner A, Bolondi L, et al. Updated use
of TACE for hepatocellular carcinoma treatment: How and
when to use it based on clinical evidence[J]. Cancer Treat Rev,
2019,72:28-36.DOI: 10.1016/j.ctrv.2018.11.002.
[17] 郭 志 , 滕 皋 军 , 邹 英 华 , 等 . 载 药 微 球 治
疗 原 发 性 和 转 移 性 肝 癌 的 技 术 操 作 推 荐 [J]. 中 华
放 射 学 杂 志, 2019,53(5):336-340.DOI: 10.3760/cma.
j.issn.1005-1201.2019.05.002.
[18] Varela M, Real M I, Burrel M, et al. Chemoembolization
of hepatocellular carcinoma with drug eluting beads: efficacy and
doxorubicin pharmacokinetics[J]. J Hepatol, 2007,46(3):474-481.
DOI: 10.1016/j.jhep.2006.10.020.
[19] Fuchs K, Duran R, Denys A, et al. Drug-eluting embolic
microspheres for local drug delivery - State of the art[J]. J Control
Release, 2017,262:127-138.DOI: 10.1016/j.jconrel.2017.07.016.
[20] Lencioni R, de Baere T, Burrel M, et al. Transcatheter
treatment of hepatocellular carcinoma with Doxorubicin-loaded
DC Bead (DEBDOX): technical recommendations[J]. Cardiovasc
Intervent Radiol, 2012,35(5):980-985.DOI: 10.1007/s00270-
011-0287-7.
[21] Irie T, Kuramochi M, Takahashi N. Dense accumulation
of lipiodol emulsion in hepatocellular carcinoma nodule during
selective balloon-occluded transarterial chemoembolization:
measurement of balloon-occluded arterial stump pressure[J].
Cardiovasc Intervent Radiol, 2013,36(3):706-713.DOI: 10.1007/
s00270-012-0476-z.
[22] Kim P H, Gwon D I, Kim J W, et al. The safety
and efficacy of balloon-occluded transcatheter arterial
chemoembolization for hepatocellular carcinoma refractory to
conventional transcatheter arterial chemoembolization[J]. Eur
Radiol, 2020,30(10):5650-5662.DOI: 10.1007/s00330-020-
06911-9.
[23] Chu H H, Gwon D I, Kim G H, et al. Balloon-occluded
transarterial chemoembolization versus conventional transarterial
chemoembolization for the treatment of single hepatocellular
carcinoma: a propensity score matching analysis[J]. Eur Radiol,
2023,33(4):2655-2664.DOI: 10.1007/s00330-022-09284-3.
[24] Minami Y, Minami T, Chishina H, et al. Balloon-
Occluded Transcatheter Arterial Chemoembolization for
Hepatocellular Carcinoma: A Single-Center Experience[J].
Oncology, 2015,89 Suppl 2:27-32.DOI: 10.1159/000440628.
[25] Yoshimatsu R, Yamagami T, Ishikawa M, et al. Change
in Imaging Findings on Angiography-Assisted CT During
Balloon-Occluded Transcatheter Arterial Chemoembolization
for Hepatocellular Carcinoma[J]. Cardiovasc Intervent Radiol,
2016,39(6):865-874.DOI: 10.1007/s00270-015-1279-9.
[26] Ogawa M, Takayasu K, Hirayama M, et al. Efficacy
of a microballoon catheter in transarterial chemoembolization of
hepatocellular carcinoma using miriplatin, a lipophilic anticancer
drug: Short-term results[J]. Hepatol Res, 2016,46(3):E60-E69.
DOI: 10.1111/hepr.12527.
[27] Asayama Y, Nishie A, Ishigami K, et al. Hemodynamic
changes under balloon occlusion of hepatic artery: predictor of the
short-term therapeutic effect of balloon-occluded transcatheter
arterial chemolipiodolization using miriplatin for hepatocellular
carcinoma[J]. Springerplus, 2016,5:157.DOI: 10.1186/s40064-
016-1880-7.
[28] Ishikawa T, Abe S, Inoue R, et al. Predictive
factor of local recurrence after balloon-occluded TACE with
miriplatin (MPT) in hepatocellular carcinoma[J]. PLoS One,
2014,9(7):e103009.DOI: 10.1371/journal.pone.0103009.
[29] Arai H, Abe T, Takayama H, et al. Safety and efficacy
of balloon-occluded transcatheter arterial chemoembolization
using miriplatin for hepatocellular carcinoma[J]. Hepatol Res,
2015,45(6):663-666.DOI: 10.1111/hepr.12403.
[30] Kawamura Y, Ikeda K, Fujiyama S, et al. Usefulness
and limitations of balloon-occluded transcatheter arterial
chemoembolization using miriplatin for patients with four
or fewer hepatocellular carcinoma nodules[J]. Hepatol Res,
2017,47(4):338-346.DOI: 10.1111/hepr.12754.
[31] Yoshimatsu R, Yamagami T, Ishikawa M, et al. Change
in Imaging Findings on Angiography-Assisted CT During
Balloon-Occluded Transcatheter Arterial Chemoembolization
for Hepatocellular Carcinoma[J]. Cardiovasc Intervent Radiol,
2016,39(6):865-874.DOI: 10.1007/s00270-015-1279-9.
[32] Kakuta A, Shibutani K, Ono S, et al. Temporal variations
in stump pressure and assessment of images obtained from cone-
beam computed tomography during balloon-occluded transarterial
chemoembolization[J]. Hepatol Res, 2016,46(5):468-476.DOI:
10.1111/hepr.12579.
[33] Maruyama M, Yoshizako T, Nakamura T, et al. Initial
Experience with Balloon-Occluded Trans-catheter Arterial
Chemoembolization (B-TACE) for Hepatocellular Carcinoma[J].
Cardiovasc Intervent Radiol, 2016,39(3):359-366.DOI: 10.1007/
s00270-015-1237-6.
[34] Irie T, Kuramochi M, Kamoshida T, et al. Selective
balloon-occluded transarterial chemoembolization for patients
with one or two hepatocellular carcinoma nodules: Retrospective
comparison with conventional super-selective TACE[J]. Hepatol
Res, 2016,46(2):209-214.DOI: 10.1111/hepr.12564.
[35] Kishimoto S, Miyazawa K, Terakawa Y, et al.
Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N’)
bis(myristato)]-platinum (II) suspended in Lipiodol in a newly
established cisplatin-resistant rat hepatoma cell line[J]. Jpn J
Cancer Res, 2000,91(12):1326-1332.DOI: 10.1111/j.1349-
7006.2000.tb00921.x.
[36] Hanada M, Baba A, Tsutsumishita Y, et al. Intra-
hepatic arterial administration with miriplatin suspended in an oily
lymphographic agent inhibits the growth of tumors implanted in rat
livers by inducing platinum-DNA adducts to form and massive
apoptosis[J]. Cancer Chemother Pharmacol, 2009,64(3):473-483.
DOI: 10.1007/s00280-008-0895-3.
[37] Okusaka T, Okada S, Nakanishi T, et al. Phase II
trial of intra-arterial chemotherapy using a novel lipophilic
platinum derivative (SM-11355) in patients with hepatocellular
carcinoma[J]. Invest New Drugs, 2004,22(2):169-176.DOI:
10.1023/B:DRUG.0000011793.72775.d1.
[38] Miyayama S, Yamashiro M, Shibata Y, et al.
Comparison of local control effects of superselective transcatheter
arterial chemoembolization using epirubicin plus mitomycin C
and miriplatin for hepatocellular carcinoma[J]. Jpn J Radiol,
2012,30(3):263-270.DOI: 10.1007/s11604-011-0043-6
[39] Seko Y, Ikeda K, Kawamura Y, et al. Antitumor
efficacy of transcatheter arterial chemoembolization with
warmed miriplatin in hepatocellular carcinoma[J]. Hepatol Res,
2013,43(9):942-949.DOI: 10.1111/hepr.12041.
[40] Kora S, Urakawa H, Mitsufuji T, et al. Warming effect
on miriplatin-lipiodol suspension as a chemotherapeutic agent
for transarterial chemoembolization for hepatocellular carcinoma:
preliminary clinical experience[J]. Cardiovasc Intervent Radiol,
2013,36(4):1023-1029.DOI: 10.1007/s00270-012-0537-3.
[41] I w a z a w a J , H a s h i m o t o N , O h u e S , e t a l .
Chemoembolization-induced arterial damage: Evaluation of
three different chemotherapeutic protocols using epirubicin and
miriplatin[J]. Hepatol Res, 2014,44(2):201-208.DOI: 10.1111/
hepr.12104.
[42] Matsumoto T, Endo J, Hashida K, et al. Balloonoccluded arterial stump pressure before balloonoccluded transarterial chemoembolization[J]. Minim
Invasive Ther Allied Technol, 2016,25(1):22-28.DOI:
10.3109/13645706.2015.1086381.
[43] Golfieri R, Bezzi M, Verset G, et al. Balloon-Occluded
Transarterial Chemoembolization: In Which Size Range
Does It Perform Best? A Comparison of Its Efficacy versus
Conventional Transarterial Chemoembolization, Using Propensity
Score Matching[J]. Liver Cancer, 2021,10(5):522-534.DOI:
10.1159/000516613.
[44] Hatanaka T, Arai H, Kakizaki S. Balloon-occluded
transcatheter arterial chemoembolization for hepatocellular
carcinoma[J]. World J Hepatol, 2018,10(7):485-495.DOI:
10.4254/wjh.v10.i7.485.
[45] Lucatelli P, De Rubeis G, Trobiani C, et al. In Vivo
Comparison of Micro-Balloon Interventions (MBI) Advantage:
A Retrospective Cohort Study of DEB-TACE Versus b-TACE
and of SIRT Versus b-SIRT[J]. Cardiovasc Intervent Radiol,
2022,45(3):306-314.DOI: 10.1007/s00270-021-03035-5.
[46] Kim B K, Kim S U, Kim K A, et al. Complete response
at first chemoembolization is still the most robust predictor for
favorable outcome in hepatocellular carcinoma[J]. J Hepatol,
2015,62(6):1304-1310.DOI: 10.1016/j.jhep.2015.01.022.
[47] Shirono T, Iwamoto H, Niizeki T, et al. Durable complete
response is achieved by balloon-occluded transcatheter arterial
chemoembolization for hepatocellular carcinoma[J]. Hepatol
Commun, 2022,6(9):2594-2604.DOI: 10.1002/hep4.2016.
(3 摘要 Views, 3 PDF Downloads)
Refbacks
- 当前没有refback。